Clinical Trial Update: Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating EGP-437, a dexamethasone phosphate formulation for ocular iontophoresis, for dry eye has completed; the update reports safety and effic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye

Drugs mentioned

• EGP-437 (dexamethasone phosphate (ocular iontophoresis formulation))

Snippet

Sponsor: Eyegate Pharmaceuticals, Inc. | Conditions: Dry Eye | Phase 3 | Status: COMPLETED